TriangleNCT02314169 · OUTCOME
Overall Survival (Part A)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From initiation of treatment until death, assessed up to 2 years
What was measured
Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 95% confidence interval.
Groups in this outcome
Part A: Nivolumab
This outcome measure is assessed from patients enrolled onto Part A of this study.
| Group | Source count |
|---|---|
| Part A: Nivolumab | 37 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part A: Nivolumab | 11.5 | Not reported | 7.1 | NA | The upper limit of the 95% confidence interval was not reached at the time of data analysis. |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit of the 95% confidence interval was not reached at the time of data analysis.
- group Id
- OG000
- lower Limit
- 7.1
- upper Limit
- NA
- value
- 11.5
- denoms
- counts
- group Id
- OG000
- value
- 37
- units
- Participants
- description
- Time measured from initiation of treatment till death. Kaplan-Meier analysis will be performed to estimate the median overall survival with a 95% confidence interval.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- This outcome measure is assessed from patients enrolled onto Part A of this study.
- id
- OG000
- title
- Part A: Nivolumab
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- From initiation of treatment until death, assessed up to 2 years
- title
- Overall Survival (Part A)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice